TCGA-A7-A26F-01A-21R-A169-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.420
- INTERFERON_GAMMA_RESPONSE+0.390
- IL6_JAK_STAT3_SIGNALING+0.380
- INTERFERON_ALPHA_RESPONSE+0.330
- ANDROGEN_RESPONSE+0.310
- ANGIOGENESIS+0.270
- MITOTIC_SPINDLE+0.270
- UV_RESPONSE_DN+0.270
- ALLOGRAFT_REJECTION+0.260
- TNFA_SIGNALING_VIA_NFKB+0.240
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.490
- DNA_REPAIR-0.430
- MYC_TARGETS_V2-0.380
- ESTROGEN_RESPONSE_LATE-0.350
- MYC_TARGETS_V1-0.350
- ESTROGEN_RESPONSE_EARLY-0.340
- UV_RESPONSE_UP-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- MYOGENESIS-0.290
- ADIPOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A26F-01B-04R-A22O-07 | — | D | 0.822 |
| 2 | TCGA-EW-A1IY-01A-11R-A13Q-07 | — | B | 0.797 |
| 3 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.793 |
| 4 | AUR-AFSO-TTP1-A-8-0-R-A741-41 | — | C | 0.792 |
| 5 | TCGA-D8-A27M-01A-11R-A16F-07 | — | D | 0.786 |
| 6 | 7ca9c52f-2d6e-4868-b4e8-9dd7937f6b2b | — | — | 0.783 |
| 7 | s0122308 | — | — | 0.780 |
| 8 | c22c07cb-8215-47e8-9525-074fda8d7d59 | — | — | 0.780 |
| 9 | SRR4296088 | — | cohortMD2 | 0.779 |
| 10 | SRR8518454 | — | D | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |